ASH2L induces tamoxifen resistance via H3K4me3 dependent ITGA6/ERK signaling in ER-positive breast cancer [0.03%]
雌激素受体阳性乳腺癌中ASH2L通过H3K4me3依赖性的ITGA6/ERK信号诱导对他莫昔芬的耐药性
Young-Hyeon Kye,So-Jeong Moon,Hea-Ry Cha et al.
Young-Hyeon Kye et al.
Background: Tamoxifen resistance remains a significant obstacle in oestrogen receptor (ER)-positive breast cancer. The function of absent, small, or homeotic 2-like protein (ASH2L) at chr8p11.23 in breast cancer is not en...
Attenuation of the CpG island methylator phenotype and lack of WNT signalling activation restrains Kras mutant intestinal neoplasia [0.03%]
CpG岛甲基化表型的减弱以及缺乏WNT信号转导活化限制了Kras突变体肠道肿瘤的发生发展
Lochlan Fennell,Cheng Liu,Alexandra Kane et al.
Lochlan Fennell et al.
Background: Serrated neoplasia arises from serrated precursor lesions. Hyperplastic polyps commonly activate MAPK signalling, initiated by BRAF or KRAS mutation, but premalignant KRAS-mutant sessile serrated lesions are r...
Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer [0.03%]
用于探索新辅助奥沙利铂诱导的尼伏单抗反应的标志物在转移性微卫星稳定型结直肠癌中的应用
Anne Hansen Ree,Paula A Bousquet,Tina Visnovska et al.
Anne Hansen Ree et al.
Background: The randomised METIMMOX trial evaluated short-course oxaliplatin-based chemotherapy alternating with nivolumab for metastatic microsatellite-stable/mismatch repair-proficient colorectal cancer. In a post hoc a...
Tumour-infiltrating lymphocyte therapy in melanoma: ready for prime time? [0.03%]
肿瘤浸润淋巴细胞疗法治疗黑色素瘤：准备就绪？
Rachel Woodford,Paul Lorigan,Deemesh Oudit et al.
Rachel Woodford et al.
Tumour infiltrating lymphocyte (TIL) therapy offers the potential for durable clinical benefit in select patients with advanced melanoma, especially after progression on treatment with immune checkpoint inhibitors and/or targeted therapies....
Correction to: Elevated APOBEC3B expression drives a kataegic-like mutation signature and replication stress-related therapeutic vulnerabilities in p53-defective cells [0.03%]
Correction to: APOBEC3B高表达驱动 kataegis 类似突变特征并导致 p53 缺陷细胞出现复制压力相关的治疗敏感性缺陷细胞出现复制压力相关的治疗弱点
Jenni Nikkilä,Rahul Kumar,James Campbell et al.
Jenni Nikkilä et al.
Published Erratum
British journal of cancer. 2026 Feb 16. DOI:10.1038/s41416-026-03352-x 2026
Natalia Khalaf,Gabriel Sandoval,Andrew J Zimolzak et al.
Natalia Khalaf et al.
Background: Over half of patients with pancreatic cancer experience an emergency cancer diagnosis, but tools for large-scale study are lacking. Towards this end, we developed a digital quality measure (dQM) to automate th...
Claudia Montiel Equihua,Jan J Molenaar,Itziar Areso et al.
Claudia Montiel Equihua et al.
Rhabdoid tumours (RT) are malignancies of the central nervous system, kidneys, liver and soft tissues that most commonly affect very young children with survival rates below 30% in high-risk cohorts. Treatment entails surgery, intensive che...
Retraction Note: Circular RNA 0000096 affects cell growth and migration in gastric cancer [0.03%]
撤回 notice: circular RNA 0000096影响胃癌细胞的生长和迁移
Peifei Li,Huilin Chen,Shengcan Chen et al.
Peifei Li et al.
Exposure-response relationship of nivolumab and ipilimumab in patients with metastatic renal cell carcinoma from the randomised phase 2 BIONIKK study [0.03%]
纳武单抗和伊匹单抗治疗转移性肾细胞癌患者的剂量-效应关系：BIONIKK 随机II期研究
Benoit Blanchet,Alicja Puszkiel,Anne Jouinot et al.
Benoit Blanchet et al.
Background: We aimed to investigate the exposure-response (E/R) relationship for ipilimumab and nivolumab in metastatic clear cell renal cell carcinoma (m-ccRCC) patients from the randomised phase 2 BIONIKK trial (EudraCT...
Real-world use and survival outcomes of sacituzumab govitecan in metastatic triple-negative breast cancer and hormone receptor-positive/HER2-negative metastatic breast cancer [0.03%]
靶向治疗药物sacituzumab govitecan在转移性三阴乳腺癌及激素受体阳性/her2阴性转移性乳腺癌中的使用情况和生存预后分析
Aya Elhusseiny Shaaban,Hugo Jourdain,David Desplas et al.
Aya Elhusseiny Shaaban et al.
Background: Sacituzumab govitecan (SG) was granted early access in France as third-line therapy for metastatic triple-negative breast cancer (mTNBC) and hormone receptor-positive/HER2-negative (HR+/HER2-mBC) metastatic br...